Deinove

Latest news

01.10.2020

2020 Half-year results: Stronger financial position and research programs moving forward despite the international context

Clinical program for the antibiotic candidate DNV3837 continues, with the support of investigators...

15.07.2020

DNV3837 antibiotic candidate: the Phase II trial continues in the United States, despite a disrupted context due to the COVID-19 outbreak

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses its lead generation...

More press releases

Antibiotic resistance, a global health challenge

The development of antibiotic resistance is, according to international organizations and governments, one of the major health challenges of the 21st century

More info

In the Medias

12.05.2020

Cdiff Foundation | A New Parenteral Treatment for a Severe C. difficile Infection

"A New Parenteral Treatment for a Severe C. difficile Infection" hosted by Nancy C. Caralla Join us with our two guests: Dr Yannick Pletan...

08.05.2020

Biotech & Finance | Alexis Rideau, arrive chez Deinove avec son réseau industriel et académique de pointe

C’est une nouvelle aventure pour Alexis Rideau, qui occupe depuis cette semaine la fonction de directeur général délégué de Deinove...

More press coverage

Disruptive innovation

Latest news

Antibiotic resistance, a global health challenge

In the Medias